Drugs / SYO-1644
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03674060 | Oct 2018 → Feb 2019 | — | Samyang Biopharmaceuticals Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYO-1644 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03674060 ↗ |
| Route | Oral | “after orally administrating SYO-1644” NCT03674060 ↗ |